BioStock: Saniona one step closer to clinical studies in HO and PWS

Saniona has completed the submission of all information previously requested by the FDA regarding its chemistry, manufacturing and controls (CMC) program for Tesomet capsules. As a result, the company expects to be able to initiate clinical phase IIb studies in the rare diseases Hypothalamic Obesity and Prader-Willi Syndrome with Tesomet this year, as planned.

Read the full article about Saniona at biostock.se:

https://www.biostock.se/en/2021/10/saniona-one-step-closer-to-clinical-studies-in-ho-and-pws/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se